2026-10-13T23:52:33Z https://data.mendeley.com/oai

oai:data.mendeley.com/k8p3xktjz2.1 2024-01-11T07:32:39Z

Zhou, Kunli Decoding real-world outcomes: exploring clinical features associated with efficacy in patients treated with dupilumab. Mendeley Supplements. Mendeley Data 1. Supplemental Materials including: Supplemental Table 1: Patients’ demographics and baseline disease characteristics. Supplemental Table 2: Patient-reported outcomes with treatment of dupilumab in 16 weeks among different age groups. Supplemental Table 3: Associations between patients’ characteristics and EASI-75 at week 16 among different age groups. Supplemental Table 4: Adverse events while on dupilumab therapy among different groups. Supplementary Figure 1: Graphical abstract. Supplementary Figure 2: Predictability of week 16 EASI-75 responses by PP-NRS change from baseline at week 2 with dupilumab. 2.Supplemental Methods Biologicals Clinical Assessment Atopic Dermatitis Efficacy Assessment Dataset doi:10.17632/k8p3xktjz2.1 oai:data.mendeley.com/k8p3xktjz2.1 Creative Commons Attribution 4.0 International http://creativecommons.org/licenses/by/4.0 https://data.mendeley.com/datasets/k8p3xktjz2 2024-01-11T07:32:39Z